Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The economic costs of NIDDM.

Literature DB >> 1307526

The economic costs of NIDDM.

T J Songer¹.

Abstract

Mesh：

Year: 1992 PMID： 1307526 DOI： 10.1002/dmr.5610080406

Source DB: PubMed Journal: Diabetes Metab Rev ISSN： 0742-4221

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Costs of diabetes. A methodological analysis of the literature.

Authors: E Pagano; M Brunetti; F Tediosi; L Garattini
Journal: Pharmacoeconomics Date: 1999-06 Impact factor: 4.981

2. Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.

Authors: Bruce E Maryanoff; John C O'Neill; David F McComsey; Stephen C Yabut; Diane K Luci; Alfonzo D Jordan; John A Masucci; William J Jones; Marta C Abad; Alan C Gibbs; Ioanna Petrounia
Journal: ACS Med Chem Lett Date: 2011-04-18 Impact factor: 4.345

Review 3. Evaluative approaches to type II diabetes.

Authors: A Triomphe
Journal: Pharmacoeconomics Date: 1995 Impact factor: 4.981

Review 4. Economic evaluations of type II diabetes.

Authors: B Leese
Journal: Pharmacoeconomics Date: 1995 Impact factor: 4.981

5. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.

Authors: P K Schädlich; J G Brecht; M Brunetti; E Pagano; B Rangoonwala; E Huppertz
Journal: Pharmacoeconomics Date: 2001 Impact factor: 4.981

Review 6. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.

Authors: R H Foster; G L Plosker
Journal: Pharmacoeconomics Date: 2000-09 Impact factor: 4.981

7. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decision-analytical approach.

Authors: K Banz; R Dinkel; M Hanefeld; U Schwanebeck
Journal: Pharmacoeconomics Date: 1998-04 Impact factor: 4.981